Gyre Therapeutics (GYRE) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue rose 20% year-over-year to $30.6 million, driven by ETUARY®, Etorel®, and Contiva® sales and new product launches.

• GAAP net income doubled to $5.9 million for Q3 2025, with net income attributable to common stockholders of $3.6 million.

• Operating income increased 64% to $6.9 million, and basic EPS improved to $0.04; diluted EPS was $0.03.

• Nine-month revenue reached $79.4 million, with net income of $11.2 million and cash and equivalents totaling $80.3 million as of September 30, 2025.

• Commercial launches of Etorel® and Contiva® in 2025 contributed to revenue growth and market expansion.

Financial highlights

• Q3 2025 revenue: $30.6 million (up from $25.5 million in Q3 2024); nine-month revenue: $79.4 million (up from $77.9 million in 2024).

• Q3 2025 gross profit: $28.9 million (18% increase); nine-month gross profit: $75.7 million (1% increase).

• Q3 net income: $5.9 million (vs. $2.9 million prior year); adjusted net income: $8.8 million.

• Q3 2025 EPS: $0.04 basic, $0.03 diluted; nine-month EPS: $0.08 basic, $0.04 diluted.

• Operating income for Q3 2025: $6.9 million (64% increase); nine-month operating income: $11.4 million (down 27%).

Outlook and guidance

• Full-year revenue guidance revised to $115–118 million (from $118–128 million) due to delayed Etorel® rollout and procurement uncertainty.

• Anticipates continued revenue growth in Q4 2025, driven by expansion of new product franchises and refocused marketing on ETUARY®.

• Plans to file a New Drug Application for Hydronidone in the PRC and initiate a Phase 2 trial in the U.S. in 2026.

• Guidance assumes constant currency and no major economic disruptions.

• Ongoing investment in commercialization and R&D to support long-term growth.